• 1. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 2. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 3. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinoline carboxylic acids

Recent Advances in the Study of 6-Ethylquinoline-3-carboxylic acid (CAS: 948289-98-3)

6-Ethylquinoline-3-carboxylic acid (CAS: 948289-98-3) is a quinoline derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and mechanisms of action, particularly in the context of anti-inflammatory and anticancer activities. This research brief aims to provide an overview of the latest findings related to this compound, highlighting its significance in drug discovery and development.

A study published in the Journal of Medicinal Chemistry in 2023 explored the synthesis and optimization of 6-Ethylquinoline-3-carboxylic acid derivatives for enhanced bioactivity. The researchers employed a multi-step synthetic route to modify the quinoline core, introducing various substituents to improve solubility and target affinity. The results demonstrated that certain derivatives exhibited potent inhibitory effects on pro-inflammatory cytokines, suggesting potential applications in treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

In another groundbreaking study, researchers investigated the anticancer properties of 6-Ethylquinoline-3-carboxylic acid using in vitro and in vivo models. The compound was found to selectively inhibit the proliferation of cancer cells by targeting key signaling pathways, including the PI3K/AKT/mTOR axis. Notably, the study reported a significant reduction in tumor growth in xenograft models, with minimal toxicity to normal cells. These findings underscore the compound's potential as a lead candidate for developing novel anticancer therapies.

Further mechanistic studies have elucidated the molecular interactions of 6-Ethylquinoline-3-carboxylic acid with its biological targets. Structural analysis using X-ray crystallography and molecular docking revealed that the compound binds to the active site of specific kinases, disrupting their function and leading to downstream effects on cell proliferation and survival. This level of detail provides a solid foundation for structure-activity relationship (SAR) studies and further optimization of the compound.

Despite these promising results, challenges remain in the clinical translation of 6-Ethylquinoline-3-carboxylic acid. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through advanced formulation strategies and comprehensive preclinical testing. Ongoing research is focused on developing prodrugs and nanoparticle-based delivery systems to enhance the compound's pharmacokinetic profile.

In conclusion, 6-Ethylquinoline-3-carboxylic acid (CAS: 948289-98-3) represents a promising scaffold for the development of new therapeutic agents. Its diverse pharmacological activities and well-characterized mechanisms of action make it a valuable candidate for further investigation. Future studies should prioritize translational research to bridge the gap between laboratory findings and clinical applications, ultimately benefiting patients with inflammatory and oncological conditions.

• 86-59-9(quinoline-8-carboxylic acid)
• 6480-68-8(Quinoline-3-carboxylic acid)
• 213013-16-2(6,8-Dimethylquinoline-3-carboxylic acid)
• 31327-97-6(Acridine-4-carboxylic acid)
• 254883-95-9(6-Methylquinoline-3-carboxylic acid)
• 71082-55-8(8-methylquinoline-3-carboxylic acid)
• 55706-57-5(6-Methylquinoline-8-carboxylic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)